Only days after highlighting abstracts for its upcoming presentations at the American Society of Hematology (ASH) meeting in Atlanta and CEO Ron Squarer's assertion that his firm was "evolving into a late-stage development company" with five programs moving toward pivotal decisions in 2013, Array BioPharma Inc. is doubling its cash position with a $65.7 million public offering.